To assess whether BCMA can be used as a target in B-NHL and CLL, we studied whether BCMAxCD3 BsAb (teclistamab, JNJ-7957) could mediate T-cell activation as well as killing of the lymphoma cell lines. Here, TNFRSF17 is linked to B-cell chronic lymphocytic leukemia.